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A critical analysis of prognostic factors for survival in intermediate and
high grade non-Hodgkin's lymphoma
R.L. Hayward', R.C.F. Leonard2 & R.J. Prescott3 with the members of the Scotland and
Newcastle Lymphoma Group Therapy Working Party*
'Medical Student, University of Edinburgh; 2Department of Clinical Oncology, Western General Hospital, Edinburgh; and
3Medical Statistics Unit, Department of Community Medicine, University of Edinburgh Medical School, UK.
Summary Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with
Working Formulation high or intermediate grade non-Hodgkin's lymphoma. Clinical, pathological and
investigational data were recorded prospectively on a computer database allowing analysis for prognostic
factors. We have derived prognostically important characteristics and have tested prospectively the validity of
the prognostic index on a geographically distinct sub-set of patients from the Edinburgh/Borders clinics.
Multivariate analysis showed the following factors to be important in declining order of power; advancing age,
worsening performance status, CNS/liver involvement, abnormal white cell count, 'B' symptoms and advanc-
ing clinical stage. Patient individual scores allowed them to be aggregated into one of three distinct prognostic
groupings separated by arbitrary cut-points into a Best Group (39%) where the median survival exceeds 5
years (53% alive at 5 years), an Intermediate Group (30%) with median survival of 21 months (21% alive at 5
years), and a Worst Group (31%) whose median survival is 7 months (8% alive at 5 years). Similar prognostic
group separations occurred when analysis was confined to: patients younger than 70 years; patients treated
with initial chemotherapy; patients treated with initial radiotherapy; patients within any of the major
pathological sub-groups.
In 1974 and 1975, DeVita and colleagues reported 37%
prolonged disease free survival in patients with advanced
stage diffuse histiocytic non-Hodgkin's lymphoma (DHL).
Because relapses were rare beyond 2 years follow up, it was
suggested that complete remissions lasting longer than 2
years could be considered cures (Schein et al., 1974; DeVita
et al., 1975; Bonnadonna et al., 1976).
Since that time increasingly complex chemotherapy regi-
mens have been designed in an attempt to achieve higher
complete remission rates. The assumption has been that more
complete remissions will lead to more cures, despite recent
evidence that disease-free survival continues to fall with pro-
longed follow-up (Fisher et al., 1987; DeVita et al., 1988).
However, many of these trials were conducted in single
tertiary referral centres, amongst younger patients than those
seen in primary referral centres in the United Kingdom or
Europe (Table I). Concern has grown that the majority of
NHL patients were not in fact benefiting to the expected
degree through the application of complicated, expensive and
toxic regimes.
In this paper, we describe the actual survival experience of
unselected high and intermediate grade non-Hodgkin's lym-
phoma (HIG NHL) patients treated with standard UK
chemotherapy and radiotherapy protocols by the multicentre
Scotland and Newcastle Lymphoma Group (SNLG). By
multivariate analysis we identify important presenting prog-
nostic features which will help in planning future therapy,
and in selecting patients who may warrant trials of more
intensive combination therapy. The general validity of the
multivariate prognostic index we propose was tested on an
independent group of patients, different from the analysis
group only by reason of geographical location. This in effect
is a prospective trial of the data-derived prognostic factors.
Correspondence: R.C.F. Leonard, Senior Lecturer, Department of
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Edinburgh EH4 2XU, UK.
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Materials and methods
Between 1979 and 1987, 1001 patients with HIG NHL by the
Working Formulation (The Non-Hodgkin's Lymphoma
Pathologic Classification Project, 1982) registered with the
SNLG. Median available follow-up was 47 months with
Table I Selection of patients for phase II trials
Number Median age Median Pathology
Regimen ofpatients (age range) follow-up subgroups
C-MOPP 27 51 (20-70) 48 DHL
(DeVita 75)
CHOP/HOP 244 53 ( 3-83) ns HIG NHL
(McKelvey 76)
CHOP(SWOG) 418 55 (ns) ns HIG NHL
(Fisher 87)
BACOP 25 47 (22-66) 18 DHL
(Schein 76)
BACOP 43 58 (18-76) 12 HIG NHL
(Skarin 77)
COMLA 42 52 (18-75) 33 DHL
(Sweet 80)
m-BACOD 87 48 (ns) 30 DLL
(Canellos 87)
COPBLAM 1 33 61 (26-91) 26 DHL
(Laurence 82)
COPBLAM 3 51 61 (19-83) 44 DLL
(Boyd 88)
MACOP-B 61 51 (19-75) 26 DLL
(Klimo 85)
ProMACE-MOPP 79 44 (15-73) 31 HIG NHL
(Fisher 83)
SWOG sequential Trials (Miller 88):
m-BACOD 116 54 (ns) 22 HIG NHL
ProMACE 118 54 (ns) 15 HIG NHL
CytaBOM 81 54 (ns) ns HIG NHL
MACOP-B
Notes:
1. The number of patients quoted is the number considered evaluable
by the authors of the quoted paper.
2. DHL is Diffuse Histiocytic Lymphoma.
3. DLL is Diffuse Large Cell Lymphoma.
4. HIG NHL is used where the paper reported results in a group of
patients representative of most subgroups of High and Intermediate
Grade Non-Hodgkin's Lymphoma by the Working Formulation.
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Table II Distribution of important characteristics for patients
classified by working formulation
all patients
High Grade
Intermediate Grade
FL DS DM DL LB SN
Males 7 (41) 136 (53) 67 (52) 226 (52) 33 (66) 42 (53)
ECOG 0 9 (56) 105 (43) 56 (45) 161 (38) 9 (19) 18 (25)
ECOG 1 or 2 4 (25) 122 (49) 62 (49) 215 (51) 35 (73) 37 (50)
ECOG 3 or 4 3 (19) 20 (8) 8 (6) 48 (11) 4 (8) 18 (25)
Stage 1 6 (35) 56 (22) 41 (32) 106 (25) 10 (20) 17 (22)
Stage 2 4 (24) 44 (17) 30 (23) 94 (22) 9 (18) 11 (14)
Stage 3 1 (6) 39 (15) 19 (15) 70 (16) 6 (12) 14 (18)
Stage 4 6 (35) 117 (46) 39 (30) 163 (38) 25 (50) 37 (47)
B symptoms 5 (29) 99 (40) 38 (30) 170 (40) 21 (47) 37 (47)
Liver involved 0 (0) 31 (12) 13 (10) 41 (9) 9 (18) 9 (11)
CNS involved 0 (0) 4 (2) 2 (2) 8 (2) 4 (8) 5 (6)
Gut involved 4 (24) 53 (21) 10 (8) 85 (20) 4 (8) 8 (10)
Lung involved 0 (0) 15 (6) 6 (5) 31 (7) 5 (10) 7 (9)
Anaemia 0 (0) 19 (8) 4 (3) 31 (7) 7 (14) 6 (8)
Low WBC 0 (0) 27 (11) 9 (7) 43 (10) 3 (6) 6 (8)
High WBC 3 (20) 39 (16) 8 (6) 72 (17) 13 (27) 13 (17)
Age <60 6 (35) 95 (37) 46 (35) 176 (40) 27 (54) 34 (43)
Age 60-70 7 (41) 76 (29) 39 (30) 123 (28) 11 (22) 21 (26)
Age >70 4 (24) 87 (34) 45 (35) 138 (32) 12 (24) 25 (31)
Total number 17 258 130 437 50 80
Notes:
1. FL = Follicular Large Cell; DS = Diffuse Small Cell; DM = Diffuse
Mixed Large and Small; DL = Diffuse Large Cell; LB = Lymphoblas-
tic; SN = Small Non-Cleaved Cell.
2. Numbers in brackets are percentages of the total in that pathological
category.
Figure 1 Age distribution of all patients.
range of 0 to 97 months. The end point used was death from
any cause. Detailed records in standard format on clinical,
haematological, radiological, pathological, treatment and re-
sponse data were available. Twenty-nine of the 1001 were
aged less than 18 years. Analysis was restricted to 972 adults.
Characteristics of patients grouped by their working formula-
tion classification are shown in Table II. For the purposes of
this report, the diffuse large cell (DLL) category includes
centroblastic and immunoblastic lymphomas. Age distribu-
tion is shown in Figure 1. Median age of all 1001 patients
was 63 years, and of the 972 adults was 64 years.
Patients were staged by standard techniques. All patients
underwent physical examination and routinely had measure-
ments of haematology and biochemistry, a chest X-ray, and
either ultrasound scan, computed tomography or lymphan-
giogram to stage abdominal disease. Bone marrow routinely
comprised trephine and aspiration examination.
Treatment included a variety of regimens. Twenty-five
patients had missing treatment data. Twenty-four received
surgery with curative intent, mostly for early stage GI tract
disease. One hundred and eight received less than attempted
curative therapy from physicians in SNLG, mostly due to
very rapid demise, or to the patient moving home locality
prior to completing treatment. One hundred and ninety-two
patients received radical radiotherapy alone. Four hundred
and ninety-five patients received 'curative' chemotherapy
alone. One hundred and twenty-eight patients received com-
bined modality therapy. Of the 623 patients who received
chemotherapy, 192 received variations on the C-MOPP
regime (with or without prednisone or procarbazine, cyclo-
phosphamide exchanged for mustine), 280 received variations
on the CHOP regime (with or without bleomycin or metho-
trexate), 99 received variations of the BACOP regime (e.g.
with or without methotrexate) and 52 received alternating
cycles of CHOP with an etoposide containing regimen. The
majority of patients were treated at the discretion of the
attending physician. A minority of patients were taking part
in controlled trials of one chemotherapy regime against
another (current SNLG trial).
Univariate survival analysis (Breslow, 1970) was used to
select any factor showing an association with death. For
example univariate analysis of pathology by the Working
Formulation showed it to be significant at P<0.05. Factors
showing such an association were included in the multi-
variate analysis.
To provide an independent test group on which to validate
our prognostic index all patients presenting to a single centre,
Edinburgh and Borders (EB), were excluded arbitrarily from
multivariate analysis. This was felt by the advising statistician
to be the least biased technique of providing a test group.
There were 310 of these patients leaving 662 patients from
other centres available for multivariate analysis.
Multivariate analysis used Cox's proportional hazards
model (Cox, 1972). Factors of least prognostic significance
were eliminated one by one in a manual step-down proce-
dure, to maximise data inclusion. Step-down continued until
all remaining variables were significant at P< 0.05. The
alternative approach, an exhaustive step-up procedure,
adding one variable to the model at a time until no new
variable was significant at P<0.05, yielded the same final
prognostic index.
Factors examined for prognostic significance included age,
sex, performance status (ECOG rating 0 to 4), previous
malignancy, centre of diagnosis, Rappaport and Working
Formulation histopathology subgroups, clinical stage,
number of nodal sites involved, extranodal sites of origin or
involvement including all major organ systems as well as
thyroid, thymus, bone and skin, nodal sites of involvement
including Waldeyer's ring, B symptoms as a group and
individually (weight loss, fever, night sweats), rashes, erythro-
cyte sedimentation rate, haemoglobulin, platelet count, white
blood count (differential white cell counts were not recorded
in the database). Evidence of organ involvement was defined
as reasonable certainty of organ involvement on clinical,
radiological or pathological grounds. Clinical stage followed
the Ann Arbor definitions, and does not represent patho-
logical stage when used in this model. B symptoms were
present if any one of fever, night sweats or weight loss were
present. Continuous variables were treated in a number of
different ways, as linear continuous variables, as transforma-
tions of the continuous variable or as a series of discrete
intervals by the use of multiple cutpoints. All of these
treatments of the continuous variables were tested separately
for prognostic significance, to choose the most informative
approach.
Information on bulk disease was only available for patients
diagnosed in the last 2 years of study and therefore the
prognostic significance of bulk of disease could not be
analysed. However number of extranodal sites of disease was
recorded and analysed.
A number of investigations were excluded from initial
analysis because data was complete for <80% of patients.
These included lymphogram, bone scan or X-rays, gallium
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scan, computed tomography or ultrasound scan of abdomen,
staging laparotomy, marrow trephine or marrow aspiration.
Our strategy for analysing these investigations was, first, to
derive a basic prognostic model using more general present-
ing features as listed above. These investigations contributed
indirectly to that analysis via their influence on clinical stage
or evidence of organ involvement. Having derived this basic
prognostic index, we then added the specific results of these
excluded investigations, one by one, back into the model,
thereby minimising data loss. We could thus identify specific
investigations which would improve significantly the prog-
nostic accuracy of our more general, basic model. There were
none. This means that use of the index does not demand the
performance of any single specific extra investigation.
Our strategy for analysing treatment was similar. First we
excluded treatment data from analysis, thus deriving a
general prognostic model on all patients, based solely on
presenting features. We then analysed the significance of
adding treatment data (by a step up procedure) to the basic
model. The model was not improved by the inclusion of
treatment data. We also looked for statistically significant
interactions between treatments and other prognostic vari-
ables which might have suggested that different models
would be appropriate for different treatment groups. There
were none, suggesting that the index could be effectively
applied to any treatment sub-group. As a final check of this
general applicability across treatments, we validated the
index on the independent group of EB patients stratified by
treatment received. The results are discussed below.
Response data were excluded from analysis because the
aim was to identify presenting features of prognostic signi-
ficance for survival, and these are often obscured by includ-
ing response in a multivariate analysis.
Results
Best survival was predicted for fit young patients with stage I
or 2 disease, no liver or CNS involvement, no B symptoms
and a normal white cell count.
Independent adverse prognostic features (in declining order
of strength) were advancing AGE, declining PERFOR-
MANCE STATUS (ECOG), involvement of CNS, involve-
ment of LIVER, abnormal WHITE CELL COUNT, B
SYMPTOMS and advanced STAGE.
Prognosis worsened in linear fashion with advancing age.
ECOG rating 1 or 2 was worse than ECOG rating 0. ECOG
rating 3 or 4 was worse than ECOG rating 1 or 2.
Abnormal white cell count was defined as < 4 or > 11 x
109/l. Deviations at either extreme carried the same addi-
tional risk. Clinical stage 1 and 2 were equivalent. Clinical
stage 3 or 4 carried the same additional risk over clinical
stage 1 or 2. Liver involvement, or CNS involvement, carried
additional prognostic significance, over and above their influ-
ence on clinical stage. Marrow involvement, as evidenced by
trephine biopsy or aspiration, had no additional significance
beyond its influence on clinical stage. Extranodal and nodal
sites of origin were not significant prognostic features. The
number of involved sites was also not a significant prognostic
factor.
Cox's model provided coefficients reflecting the prognostic
importance of the significant factors. Using these coefficients
a simple, additive, multivariate prognostic index could be
constructed, and any patient assigned an index score (Table
III). A high score predicted poor prognosis.
The coefficients themselves are difficult to interpret in real
terms so, to provide a meaningful impression of the real
significance of these prognostic features we have also express-
ed their influence in terms of relative risk, listed in column X
of Table III. Relative risk refers to the number of times a
patient's risk of death is multipled at any time, given the
presence of an adverse prognostic feature. The influence of
any two features is multiplicative so that for example the
presence of ECOG rating 2 and B symptoms means risk of
death is multiplied by (1.7 x 1.5) = 2.55-fold. The death rate
Table III Coefficients for deviations from best risk status
Coeff X
Fitness rating 1 or 2 (ECOG rating) 0.53 1.7
Fitness rating 3 or 4 (ECOG rating) 1.3 3.6
Clinical stage 3 or 4 0.29 1.3
Any B symptoms 0.42 1.5
Abnormal white count (<4 or > I I x 109/1) 0.42 1.5
Liver involvement 0.48 1.6
CNS involvement 0.7 2.0
Every year of age 0.023 1.023
Simple additive index created using coefficients- high score implies
poor prognosis. e.g. 60 year old patient, fitness 2, stage 4 with liver
involved but no B symptoms and normal white count scores:
(60 x 0.023 for age) + (0.053 for fitness) + (0.29 for stage)
+ (0.48 for liver involvement = 2.68
and falls into the worst prognostic group. Best Prognostic Group< 2.0,
Intermediate Prognostic Group 2.0 -2.6, Worst Prognostic Group> 2.6.
for all patients provided the mean prognostic reference score
of 1.
The index was applied to all patients in the,analysis group,
and cutpoints chosen to separate a lowest scoring 33% (best
predicted survival) from an intermediate 33% and a highest
scoring 33% (worst predicted survival). These cutpoints were
essentially arbitrary, and different cutpoints could be chosen
to separate different proportions of patients.
Applying the index and cutpoints to the independent group
of 310 EB patients validated the index.
Figure 3 shows overall survival of all patients presenting to
EB and treated with conventional chemotherapy and/or
radiotherapy. No plateau survival is apparent, median sur-
vival is 23 months and 5 year survival is only 31%. This
overall survival curve for EB patients is similar to that for all
patients from all centres (Figure 2).
Figure 4 shows survival of the EB group stratified by index
score. The index separates three distinct prognostic sub-
groups.
In particular a worst surviving group (30% of patients),
with median survival of only 7 months and 5 year survival of
8%, can be identified. Characteristics of patients from all
centres who fall into this group are shown in Table IV.
The intermediate group (31% of patients) had median
survival of 21 months and 5 year survival of 21%. Charac-
teristics of patients from all centres who fall into this group
are shown in Table IV.
Although no plateau survival emerged in the best group(39% of patients), median survival was not reached and 5
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Figure 2 Overall survival of all patients from all centres.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals. All patients with complete data for the
index are included.
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Table IV Distribution of cases in each prognostic group
(by percentages)
Intermediate
Best group group Worst group
Factor (n = 304) (n = 278) (n = 284)
Male sex 55% 47% 55%
ECOG PS
0 84% 25% 4%
1-2 16% 73% 65%
3-4 0% 2% 31%
Clin stage
1-2 64% 49% 18%
3-4 36% 51% 82%
'B' symptoms 13% 34% 74%
Liver involved* 2% 8% 24%
Anaemia 4% 6% 12%
Abnormal WCC 8% 19% 49%
Age <70 89% 59% 55%
Age >70 11% 41% 45%
Du u *Other extra-nodal sites were approximately equally represented in
the prognostic groups, being 0- 5% for CNS, 13 -22% for GI Tract and
47 29 4-12% for lung.
Figure 3 Overall survival of all Edinburgh and Borders patients.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals. All patients with complete data for the
index are included.
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Figure 4 Survival of Edinburgh and Borders patients grouped
by index score.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals for each group. All patients with complete
data for the index are included.
year survival (53%) for this group approached that claimed
in North American trials. Characteristics of patients from all
centres who fall into this group are shown in Table IV.
The index was similarly validated on younger patients
(aged <70 years) since in future it may be used to select
patients for aggressive therapies. Figure 5 shows equally
good separation of three distinct prognostic groups amongst
patients under 70 years.
The best group (47% of patients) had 5 year survival of
54% and did not reach median survival.
The intermediate group (27% of patients) had median
survival of 26 months and 5 year survival of 28%.
The worst group (25% of patients) had median survival of
9 months and 5 year survival of 9%. Thus a very poorly
surviving group of relatively fit patients younger than 70 is
identified.
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Figure 5 Survival of Edinburgh and Borders patients less than
70 years of age: patients grouped by index score.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals for each group. All patients with complete
data for the index are included.
The index was also validated by testing it on a variety of
subgroups of the independent EB patients.
Thus when restricted to 155 DLL patients the best group
had 5 year survival of 54%, the intermediate group 5 year
survival of 31 %, and the worst group 5 year survival of 11%
(Figure 6).
When restricted to 96 diffuse small cell lymphoma (DSL)
patients, the best group had 5 year survival of 53%, the
intermediate group 5 year survival of 17%, and the worst
group 5 year survival of 0% (Figure 7). Similar patterns were
seen in the other smaller histopathological groups.
When restricted to 170 stage 3 or 4 patients, the best group
had 5 year survival of 44%, the intermediate group 5 year
survival of 18%, and the worst group 5 year survival of 9%
(Figure 8).
When restricted to 137 stage 1 or 2 patients, the best group
had 5 year survival of 59%, the intermediate group 5 year
survival of 23%, and the worst group 5 year survival of 8%
(Figure 9).
The index was also valid when tested on subgroups of EB
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Figure 6 Survival of Edinburgh and Borders patients with
diffuse large cell lymphomas: patients grouped by index score.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals for each group. All patients with complete
data for the index are included.
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Figure 8 Survival of Edinburgh and Borders patients with stage
III or IV disease: patients grouped by index score.
Numbers of patients remaining at risk are shown below the x-axis
of 14 month intervals for each group. All patients with complete
data for the index are included.
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Figure 7 Survival of Edinburgh and Borders patients with
diffuse small cell lymphoma: patients grouped by index scores.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals for each group. All patients with complete
data for the index are included.
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Figure 9 Survival of Edinburgh and Borders patients with stage
I and II disease: patients grouped by index score.
Numbers of patients remaining at risk are shown below the x-axis
at 10 month intervals for each group. All patients with complete
data for the index are included.
patients stratified by treatment received. Three discrete prog-
nostic groups are separated amongst patients who went on to
receive radiotherapy and also amongst patients who went on
to receive chemotherapy. Thus of 85 patients receiving radio-
therapy during first line treatment, the best group had 5 year
survival of 48%, the intermediate group 5 year survival of
25%, the worst group 5 year survival of 11% (Figure 10). Of
186 patients receiving chemotherapy during first line treat-
ment, the best group had 5 year survival of 55%, the inter-
mediate group 5 year survival of 22% and the worst group 5
year survival of 8% (Figure 11). Further subdivision by
specific chemotherapy regimen could not be performed
because numbers in each group became too small. Never-
theless this broad validity across major treatment subgroups
allows the identification of poorly surviving patients whatever
treatment is proposed.
Discussion
In this paper we have described the survival experience of all
patients with high or intermediate grade NHL presenting to
primary referral centres in the SNLG. It is impossible to be
sure of how completely NHL cases are registered with
SNLG. However it is the case that the participating hospitals
draw patients from a relatively well defined geographical
950 R.L. HAYWARD et al.
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et al., 1988). Thus censoring patients from survival analysis
when they die of 'other causes', assuming these can be
809 1 An accurately defined, may result in an over-optimistic estimate
of disease free survival, since these deaths will occur in
generally older and less fit patients, who may be the most
60 '1 Illikely to relapse. To avoid these problems, and because ourinterest is in the real survival expectations we can offer our
patients, we decided to use as our endpoint death from any
40 L1 [ cause. Coleman has recently suggested that this is the most
appropriate and reproducible endpoint to choose (Coleman
et al., 1987).
20 i Several important features are apparent in the overall sur-
vival data for all our patients, with all stages and pathologies
within high and intermediate NHL (Figure 2). The median
o. __ survival is 23 months. There is no evidence of a plateau
0 7 14 21 28 35 42 49 56 63 beyond 2 years, though some decline is to be expected
Months through attrition unrelated to lymphoma. Five year survival
44 32 18 15 10 is only 31%. If we examine patients with stage 3 and 4
disease alone, median survival is 15 months, with again no
19 9 7 4 3 evidence of a plateau, and 5 year survival of 22%. Patients
16 4 2 1 1 with stage 1 or 2 disease have median survival of 38 months,
Survival of Edinburgh and Borders patients who no plateau, and 5 year survival of 40%. Examining advanced
diotherapy during first line treatment patients grouped stage DLL patients alone, median survival is 14 months, no
score. plateau is apparent, and 5 year survival is 24%.
)f patients remaining at risk are shown below the x-axis These data contrast unfavourably with results reported for
th intervals for each group. All patients with complete many small therapeutic trials in specialist referral centres in
he index are included. the USA. Optimistic reviews of NHL therapy have summar-
ised the apparent progress due to the application of increas-
ingly complex chemotherapy (Coleman et al., 1988; DeVita et
al., 1988). ProMACE-MOPP, ProMACE-CytaBOM, M-
BACOD, m-BACOD, COP-BLAM and its refinements, and
MACOP-B are all contemporary variations on this theme
80 ll lll (Fisher et al., 1983; Fisher et al., 1987; Skarin et al., 1983;
Canellos et al., 1987; Laurence et al., 1982; Boyd et al., 1988;
Klimo & Connors, 1987). However response and survival
60 15XL
were significantly related to several patient and disease char-
acteristics (Fisher et al., 1977; Cabanillas et al., 1978; Len-
hard et al., 1978; Stein et al., 1979; Fisher et al., 1981;
Armitage et al., 1982; Trump & Mann, 1982; Leonard et al.,
40 1983; Sullivan et al., 1983; Al-Katib et al., 1984; Steward et
al., 1984; Horning et al., 1984). The patients treated at
different centres often differed widely as a result of selection
20 pressures occurring in the referral process. Differences in age,
st,age marrow involvement and CNS disease were all suggest-
ed as potential reasons for differing results (Stein, 1984
(letter); Fisher et al., 1984 (letter); Honegger & Cavalli, 1984;
Coleman et al., 1987).
0 10 20 30 40 50 60 Indeed, when a single multicentre group carried out sequen-
Months tial trials of CHOP, m-BACOD, ProMACE-CyTABOM and
62 50 41 31 23 18 10 MACOP-B, they could demonstrate no advantages for the
te 60 43 28 20 9 8 5 newer regimens in terms of CR rates (Fisher et al., 1987;
55 28 13 7 5 3 2 Miller et al., 1988). When a large European series of
advanced aggressive histology patients were treated withSurvival of Edinburgh and Borders patients who alternating cycles of two non-cross resistant combinations
hinemsothra during first line treatment: patients (CVP-ABP), in a regime not dissimilar to COP-BLAM, pro-oy index score.logdDSwsntsgiiatybtethnCO rsus)f patients remaining at risk are shown below the x-axis longed DFS was not significantly better than CHOP results
th intervals for each group. All patients with complete (Monfardini et al., 1984).
he index are included. Our analysis of prognostic features provides a partial ex-
planation for these contrasts. We have derived a multivariate
prognostic index by the analysis of a large group of 662
generally provide the total National Health Service patients, a much larger group of lymphoma patients than has
esources for those regions. Thus we can with some previously been subjected to such an analysis. The validity of
suggest that this group of patients represents a the index has been demonstrated powerfully on an indepen-
unselected sample of total NHL cases occurring dent group of 310 patients selected by geography alone, a
LG boundaries. demonstration of validity not previously attempted by other
analysis we have not attempted to define lym- published analyses. Application of the index separates three
ated deaths as our endpoint. The accurate defini- distinct prognostic groups. The best has 5 year survival
use of death or status of lymphoma at death is approaching that for most small scale therapeutic trials.
)ther causes of death will be commoner amongst The two major prognostic features identified in our ana-
unfit patients. On the other hand there is evidence lysis, age and performance status, have also been identified
iced age and poor performance status may com- by other investigators as important influences on response
ke achievement or durability of complete response and survival. Both of these features are often operative in
et al., 1983; Kaminski et al., 1986; Shipp et al., selecting patients for therapeutic trials. Table I shows that
ieu et al., 1986; Lenhard et al., 1978; Al-Katib et most trials have treated patients of lower median age than
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our patients. Connors, in describing the MACOP-B pro-
gramme, mentioned the specific exclusion of unfit patients,
and patients over 70 years (Connors & Klimo, 1988). Canel-
los, describing m-BACOD, mentioned that ony 3% of
patients had ECOG rating >2, (Canellos et al., 1987). In
SWOG sequential trials of m-BACOD reduced doses were
administered to elderly or unfit patients, and these patients
achieved a CR rate of only 27%. The CR rate (67%) for the
younger fitter group was quoted as an estimate of m-BACOD
efficacy (Miller et al., 1988). In the CHOP sequential trials at
SWOG age had a powerful effect on CR and survival rates
(Dixon et al., 1986). In the COP-BLAM 3 and COP-BLAM
4 trials, where patients had at age distribution closer to
SNLG experience, age had an important effect on CR rates
or durability (Boyd et al., 1988; Coleman et al., 1988). Shipp,
who also noted fitness as an important determinant of re-
sponse and survival, drew attention to the well recognised
importance of fitness in prognosis of solid tumours, and the
lack of data concerning fitness as a prognostic factor in NHL
(Shipp et al., 1986). Other multivariate analyses have detect-
ed age as an important prognostic feature (Danieu et al.,
1986; Al-Katib et al., 1984; Homing et al., 1984; Lenhard et
al., 1978; Kaminski et al., 1986). Armitage has recently noted
that many trials select patients on the basis of age and
fitness, though often descriptions of fitness do not appear in
treatment reports (Armitage & Cheson, 1988). Our analysis
provides evidence that the selection of patients on the basis
of age or fitness is likely significantly to influence results.
This is true whether or not the selection occurs as a deliber-
ate policy, or as the result of uncontrolled pressures in the
referral process. These conculsions underline the importance
of publishing good descriptions of patients entering trials, to
allow comparisons to be made more readily (Carter, 1985).
Ideally a prognostic index might be used to estimate the
expected survival of patients in different trials.
As noted above, the two most important prognostic fac-
tors, age and performance status, have also been detected by
other investigators. The details of the index are also in broad
agreement with other analyses. CNS disease has long been
recognised as a poor prognostic feature, and indeed provided
the impetus for the introduction of high dose methotrexate
into many regimes. It would seem that our patients would
benefit from more aggressive therapy for CNS involvement.
CNS disease has been correlated with marrow disease in the
past. Perhaps this explains in part our failure to detect
marrow involvement as an independent adverse feature.
Several multivariate analyses have implicated marrow in-
volvement as a poor prognostic feature (Bloomfield et al.,
1974; Armitage et al., 1982; Fisher et al., 1981) whereas
others have not (Cabanillas et al., 1978; Leonard et al., 1983;
Shipp et al., 1986; Stein et al., 1979; Horning et al., 1984). In
our analysis the only organ site of involvement (other than
CNS) which carried additional prognostic significance
beyond its influence on stage was liver involvement. Others
have demonstrated an influence of liver involvement on prog-
nosis, by univariate analysis (Fisher et al., 1981; Stein et al.,
1979) or by multivariate analysis (Steward et al., 1984).
Interestingly Steward (1984) showed marrow involvement
was a poor prognostic feature for CR but not for survival,
whereas liver involvement carried a poor prognosis for sur-
vival but not for CR. The adverse significance of B symp-
toms has been noted in many analyses (Bloomfield et al.,
1974; Leonard et al., 1983; Steward et al., 1984; Armitage &
Cheson, 1988; Fisher et al., 1981; Sullivan et al., 1983; Al-
Katib et al., 1984). Cabanillas showed symptoms had an
adverse significance for survival but not for CR (Cabanillas
et al., 1978). One previous multivariate analysis has noted
both high and low white cell counts as adverse prognostic
features of approximately equal weight (Leonard et al.,
1983).
The failure of pathological sub-type to influence prognosis
is interesting. Whilst this was a highly significant prognostic
variable on univariate analysis, when it was included in our
multivariate index it became non-significant. This implies
that between different pathological sub-types there are impor-
tant differences in the distribution of age, stage, fitness, liver
or CNS involvement, white cell count, or B symptoms. These
differences must account in part for the crude survival differ-
ences observed between pathological sub-types. In the future,
the finer detail of pathological description afforded by
immunochemistry and molecular biological analyses may
help to refine the prognostic value of 'pathology'. When one
examines the proportion of patients with each pathological
group which fall into each prognostic group, as predicted by
the index, significant differences are apparent (Table IV).
This fact explains why a univariate analysis of prognosis by
pathological sub-type appears significant.
The failure of treatment variables significantly to improve
the index does not imply that treatment had no effect on
outcome. During the study period treatment for HIG NHL
was selected primarily on the basis of age, fitness and stage,
and so the effects of treatment are allowed for in the coeffic-
ients derived for these covariates, which are all included in
the index. It is important to recognise that, whilst the index
is applicable across the range of treatment groups in this
study, it will only remain so under the conditions that
assigned our patients to these different treatment groups.
The utility of our prognostic index is demonstrated by its
capacity to separate three distinct prognostic groups when
applied to a range of patient and treatment subgroups of our
independent EB patients. Thus as shown above it is useful
when applied to patients under 70, to DLL patients, to DSL
patients, to early stage patients, to advanced stage patients,
and to patients stratified by treatment received.
In conclusion, this simple additive index is applicable
across a range of patient and treatment groups. It uses
readily available data at presentation to allow: (1) better
prediction of survival for the individual patient; (2) strati-
fication of future treatment studies, and (3) selection of poor
risk younger patients (under 70 years) for novel or aggressive
therapy. The application of such an index to results reported
in different patient groups could facilitate better comparison
of these results. Importantly, the study also demonstrates
that patient selection could largely account for the variety of
results in earlier treatment studies.
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